Chokeberry (Aronia melanocarpa) fruit extract modulates immune response in vivo and in vitro by Gajić, Dragica et al.
Contents lists available at ScienceDirect
Journal of Functional Foods
journal homepage: www.elsevier.com/locate/jff
Chokeberry (Aronia melanocarpa) fruit extract modulates immune response
in vivo and in vitro
Dragica Gajica,1, Tamara Saksidaa,1, Ivan Koprivicaa, Milica Vujicica, Sanja Despotovicb,
Katarina Savikinc, Teodora Jankovicc, Ivana Stojanovica,⁎
a Department of Immunology, Institute for Biological Research “Sinisa Stankovic” – National Institute of Republic of Serbia, University of Belgrade, Bulevar despota Stefana
142, 11060 Belgrade, Serbia
b Institute of Histology and Embryology “Aleksandar Dj. Kostic”, School of Medicine, University of Belgrade, Visegradska 26, 11000 Belgrade, Serbia
c Institute for Medicinal Plants Research “Dr Josif Pancic”, Tadeusa Koscuska 1, 11000 Belgrade, Serbia
A R T I C L E I N F O
Keywords:
Aronia melanocarpa
Type 1 diabetes
Dendritic cells
Macrophages
T helper 1 cells
A B S T R A C T
Chokeberry (Aronia melanocarpa) is known for its anti-oxidant, anti-inflammatory and anti-diabetic properties.
Since the effects of chokeberry extract on the immune response have been only sporadically assessed, our aim
was to investigate chokeberry fruit water extract on the immune response in vivo and in vitro. When administered
orally to healthy mice, the extract exerted immunomodulatory effects in the gut evidenced by the altered
proportion of macrophages, dendritic cells and T cells. Importantly, oral consumption of the chokeberry extract
resulted in blood glucose level increase in C57BL/6 mice with chemically-induced diabetes. These in vivo results
were corroborated by observed up-regulation of nitric oxide and interelukin-1β production in macrophages and
dendritic cells, up-regulated phagocytic activity of macrophages, increased T and B lymphocytes proportions and
differentiation of interferon-γ-producing T cells in vitro. The obtained results imply that our chokeberry extract
stimulates pro-inflammatory properties in immune cells of innate and adaptive immunity.
1. Introduction
Chokeberry (Aronia melanocarpa) contains several biologically ac-
tive compounds such as phenolic acids, anthocyanins, flavonoids, and
proanthocyanidins (Banjari et al., 2017; Zheng & Wang, 2003). These
berries have a greater content of phenolic constituents than most other
black berries (Kähkönen, Hopia, & Heinonen, 2001; Wu, Gu, Prior, &
McKay, 2004). Various chokeberry extracts are commercially available
and advertised as potent supplements for the treatment of diabetes,
cancer, hypertension and stress. Generally, chokeberry juice, fruit or
leaf extracts are considered to be anti-inflammatory, anti-oxidant, hy-
poglycemic, hypolipidemic, hypotensive, anti-inflammatory and anti-
bacterial properties (Appel et al., 2015; Borowska & Brzóska, 2016;
Francik et al., 2014; Handeland, Grude, Torp, & Slimestad, 2014; Thi &
Hwang, 2018a). These statements only partly rely on the experimental
data obtained from animal studies. For example, anti-diabetic effects
were demonstrated after oral administration of a chokeberry ethanol
extract to hyperglycemic rats or ICR mice (Jeon et al., 2018; Valcheva-
Kuzmanova, Kuzmanov, Tancheva, & Belcheva, 2007). Also, clinical
trials in volunteers with hypercholesterolemia revealed that chokeberry
juice consumption reduced total cholesterol levels and mildly down-
regulated blood glucose levels (Skoczyñska et al., 2007). Apart from
these metabolic effects, chokeberry exhibits anti-inflammatory capa-
city, revealed in both in vivo and in vitro studies. Oral administration of
the chokeberry extract inhibited prostaglandin E2 production in DSS-
induced colitis in mice and decreased the levels of nitric oxide (NO),
interleukin-6 (IL-6), and tumor necrosis factor (TNF) in ex vivo lipo-
polysaccharide (LPS)-stimulated macrophages (Kang et al., 2017). Si-
milarly, the chokeberry extract down-regulated inflammation in LPS-
induced uveitis (Ohgami et al., 2005). Versatile commercial and la-
boratory-made extracts also exhibited anti-inflammatory effect in vitro:
chokeberry inhibits IL-6 and up-regulates interleukin 10 (IL-10)
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production in mouse splenocytes (Martin et al., 2014) and decreases
NO, IL-6 and TNF production in macrophages and microglia (Lee et al.,
2018; Thi & Hwang, 2018b). These anti-inflammatory effects were
primarily due to particular polyphenols (cyanidin-3-arabinoside and
quercetin) that are represented as a minor fraction of total polyphenols
of chokeberry (Martin et al., 2014). Some of the extracts display their
anti-inflammatory nature through inhibition of leukocyte transmigra-
tion from the blood into the tissue by lowering the expression of ad-
hesive molecules on endothelial cells (Zapolska-Downar et al., 2012).
Pro-inflammatory effects of chokeberry extracts have not been docu-
mented so far, except for a single result in mice with colitis, where the
up-regulation of type 17 T helper cell (Th17) proportion was found
within gut-associated lymphoid tissue (GALT) after the treatment with
the whole chokeberry powder (Pei et al., 2019).
The aim of this study was to delineate the effects of a chokeberry
extract on immune cells in healthy C57BL/6 mice and in mice with type
1 diabetes (T1D), and to evaluate whether this extract modulates im-
mune cells in vitro.
2. Material and methods
2.1. Plant material
Berries were kindly provided by Conimex Trade Ltd. Chokeberries
were collected in the fourth year of cultivation from the organic certi-
ficated experimental field near Šabac, Serbia, in August 2017. Conimex
Trade Ltd regularly performs analyses of the complete health probity of
berries to confirm the absence of contaminants. The chokeberry extract
was free of viable bacteria (tested in the Brain Heart Infusion broth),
and no endotoxin was detected (tested by PYROGENT™-5000 Kinetic
Turbidimetric LAL Assay, Lonza Netherlands B.V., Geleen, The
Netherlands). The average diameter of berries was 7.1 mm while the
average weight was 1.18 g. After collection, the chokeberries were
immediately dried at 40 °C for 48 h in a laboratory dryer
(Instrumentaria ST 01/02, Zagreb, Croatia) and grinded by a laboratory
mill at the Institute for Medicinal Plants Research, Belgrade, Serbia,
which is certified with ISO 9001:2015 and HACCP for quality stan-
dards.
2.2. Extract preparation
Plant material was extracted on an orbital shaker (170 rpm) with
50% ethanol for 60min using solid to solvent ratio 1:20 (Ćujić et al.,
2016). After the extraction, ethanol was evaporated under vacuum and
water extract was obtained. The water extract was frozen at−80 °C and
freeze-dried (Beta 1–8 Freeze Dryer, Martin Christ, GmbH, Osteroide
am Harz, Germany). Overall, from 100 g of chokeberries, 47.3 g of dried
extract were obtained.
2.3. HPLC analysis
HPLC analyses were carried out on a reverse phase Lichrospher RP-
18 (Agilent, Waldbronn, Germany) analytical column (250×4mm i.d.,
5 µm particle size) according to the previously reported method (Ćujić
et al., 2016). The results were expressed as milligram per gram of dry
extract. The content of total proanthocyanidin compounds in samples
was determined spectrophotometrically using modified p-dimethyla-
minocinnamaldehyde (p-DMACA) method (Li, Tanner, & Larkin, 1996).
The chokeberry extract (100 μg) was mixed with 80 μL of p-DMACA
reagent, 2 mL methanol, and a drop of glycerol, and the absorbance was
measured after 7min at 640 nm. The contents of proanthocyanidins in
the samples were expressed as milligrams of catechin equivalents per
gram of extract (mg CE/g).
2.4. T1D induction and treatment with chokeberry extract
Male C57BL/6 mice were bred and housed in the Institute for
Biological Research “Sinisa Stankovic”, under standard conditions with
free access to food and tap water. The Ethic Committee of the Institute
for Biological Research “Sinisa Stankovic” approved all experimental
procedures (App. No 02-11/18-01-2420), which also complied with the
ARRIVE guidelines and were in accordance with the Directive 2010/
63/EU. T1D was induced in mice (2months old) by intraperitoneal
injection of streptozotocin (STZ) (Sigma-Aldrich, St. Louis, MO, USA)
given in a dose of 40mg/kg bw during five consecutive days. This
procedure is typically used for T1D induction in C57BL/6 mice
(Cetkovic-Cvrlje, Thinamany, & Bruner, 2017; Koprivica et al., 2019).
The chokeberry extract was dissolved in water and administered orally
every day in the doses of either 200mg/kg bw or 50mg/kg bw, starting
from the first injection of STZ, for 7 days in total. Therefore, we formed
three experimental groups: (1) a control group receiving STZ; (2) a
treatment group receiving STZ and chokeberry extract (200mg/kg bw);
(3) a treatment group receiving STZ and chokeberry extract (50mg/kg
bw). Each group consisted of 7 mice. Glycemia levels were monitored
on a weekly basis from blood obtained from the tail vein using a
glucometer (Sensimac, IMACO GmbH, Lüdersdorf, Germany). Blood
glucose level in non-fasted mice higher than 11mmol/l was considered
as hyperglycemia. Diabetes incidence was calculated as proportion of
hyperglycemic mice within the total number of mice in the experi-
mental group.
To evaluate the effect of the chokeberry extract (50mg/kg bw) on
healthy mice, we formed two experimental groups of mice: a treatment
group, which received the extract orally (by gavage) for 7 days, while a
control group received the same volume of water for 7 days. Each group
consisted of 7 mice. On day 10 after the first oral consumption, ex vivo
analysis of immune cells was performed.
2.5. Isolation of intraepithelial lymphocytes
Isolation of the intraepithelial lymphocytes (IEL) was performed
according to the protocol described by Couter and Surana (2016). The
small intestine was removed aseptically, cut into pieces (approx. 3 cm
long) and cut longitudinally. After removing the intestinal content and
the Peyer’s patches, the pieces were washed thoroughly in cold RPMI
1640 medium and incubated for 15min at RT in 1mM dithiothreitol to
remove excess mucus. After centrifugation (1500 rpm, 5min), the pellet
was resuspended in RPMI medium containing 5% fetal calf serum (FCS)
(both from PAA Laboratories, Pasching, Austria), 1 mM ethylenedia-
minetetraacetic acid (EDTA), 1 mM dithiothreitol (both from Sigma-
Aldrich) and incubated for 1 h at 37 °C in an orbital shaker (speed 140/
min). The acquired suspension was filtered through a 100 μm mesh and
additionally through a 60 μm mesh and centrifuged at 1500 rpm for
5min. The pellet was resuspended in RPMI medium containing 5% FCS,
1mM EDTA and mixed with a Percoll gradient solution (40% final). It
was then layered upon 70% Percoll and centrifuged at 1500 rpm for
20min without rotor brakes. Intraepithelial lymphocytes (found in the
layer between 40% and 70% Percoll) were collected, washed twice in
phosphate-buffered saline (PBS) containing 0.5% bovine serum al-
bumin (BSA) (AppliChem GmbH, Darmstadt, Germany), 1 mM EDTA
and resuspended in RPMI 5% FCS.
2.6. Isolation of Peyer’s patches cells
Peyer’s patches (PP) were removed from the small intestine and the
cells were obtained by passing the tissue through a 40 µm mesh. After
centrifugation, the cells were resuspended in RPMI 5% FCS and
counted, after which 5x105 cells were used for flow cytometry staining
(Couter & Surana, 2016).
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2.7. Isolation of peritoneal macrophages
Peritoneal cells (PC) were obtained by lavage of the peritoneum
with 4mL of cold PBS. The samples were then centrifuged at 550g for
5min and 5× 106 cells were seeded in RPMI 5% FCS supplemented
with 1% penicillin and streptomycin in 24-well adherent plates
(Sardstedt, Numbrecht, Germany), as described by Vujicic et al. (2015).
The cells were kept in an incubator at 37 °C with 5% CO2 for 2 h, after
which the wells were washed with warm PBS to remove non-adherent
cells. The remaining cells were considered as macrophages and were
either stimulated with LPS (Sigma-Aldrich) and interferon-γ (IFN-γ) (R
&D Systems, Minneapolis, MN, USA) or kept unstimulated in the pre-
sence or absence of increasing concentrations of the chokeberry extract
(between 0.08 and 50 µg/ml, depending upon the experiment). After
performing a viability assay, the dose of 25 µg/ml of the chokeberry
extract was chosen for application in further experiments. For flow
cytometry, macrophages were detached from the adherent plates by
placing the plate on ice and by washing the cells with cold PBS.
2.8. Differentiation of dendritic cells in vitro
Dendritic cells (DC) were obtained from progenitor bone marrow
cells of C57BL/6 mice. The femur was isolated and flushed aseptically
with RPMI 10% FCS. Cells were then centrifuged, erythrocytes lysed
with red blood cells (RBC) lysis buffer (eBioscience, San Diego, CA,
USA) and the cells resuspended in RPMI 20% FCS, 2mM L-glutamine,
1 mM Na-pyruvate (PAA Laboratories). The obtained cells were culti-
vated with 20 ng/ml granulocyte-macrophage colony-stimulating factor
(Peprotech, London, UK) for 7 days with a medium change every second
day. DC differentiation was performed according to the protocol de-
scribed by Djedovic et al., 2019. DC were passaged on day 7 by enzy-
matic digestion with acutase (ThermoFisher, Waltham, MA, USA)
treatment and seeded at 5× 105 cells/well in a 96-well plate (Sard-
stedt). To induce mature DC, cells were treated with 100 ng/ml LPS on
day 7, in the presence or absence of different concentrations of the
chokeberry extract (6–50 µg/ml). Supernatants were collected 48 h
after the treatment with chokeberry extract.
2.9. Isolation of splenocytes
Spleens were removed aseptically and processed according to the
protocol described by Vujicic et al., 2015. After passing through plastic
mesh and centrifugation, erythrocytes were lysed with RBC lysis buffer
and cells were resuspended in RPMI 5% FCS. 5×106 cells were seeded
in RPMI 5% FCS and treated with concanavalin A (ConA – Pharmacia
Fine Chemicals, Uppsala, Sweden) in the presence of the chokeberry
extract (25 μg/ml). Supernatants were collected after 48 h of incubation
and flow cytometry analysis was performed.
2.10. Differentiation of Th1, Th17 and Treg cells in vitro
Naïve CD4+CD25- lymphocytes were purified from the spleens of
healthy animals. Splenocytes were first incubated with biotin-con-
jugated anti-mouse CD25 (1:100, eBioscience) for 20min on ice for
negative selection. Cells were then resuspended in cold magnetic bead
buffer (PBS 0.5% BSA, 2mM EDTA) containing BD IMag™ Streptavidin
Particles Plus - DM (1:20, BD Biosciences, Bedford, MA, USA). CD25-
cells were purified by placement in a BD IMag™ Cell Separation Magnet
(BD Biosciences), 3× for 8min. After washing in PBS, CD25- cells were
subjected to positive selection by incubation with biotin-conjugated
anti-mouse CD4 (1:60). Purified CD4+CD25- cells were resuspended in
RPMI 10% FCS, 0.02mM Na-pyruvate, 5 µM β-mercaptoethanol, 2 mM
L-glutamine, 25mM HEPES (PAA Laboratories) and antibiotics.
CD4+CD25- cells (5× 105) were seeded in U-bottom 96-well plates and
received stimuli from plate-bound anti-CD3 (1 μg/ml) and soluble anti-
CD28 antibodies (1 μg/ml) (both from eBioscience). For type 1 T helper
(Th1) differentiation the cells were additionally stimulated with inter-
leukin-12 (IL-12) (20 ng/ml, R&D Systems) and anti-interleukin-4 (IL-4)
antibody (10 ng/ml, eBioscience), for Th17 differentiation the cells
were stimulated with transforming growth factor-β (TGF-β) (10 ng/ml)
and IL-6 (10 ng/ml) (both from R&D Systems), while for T regulatory
(Treg) differentiation the cells were stimulated with TGF-β (2 ng/ml)
and interleukin-2 (IL-2) (10 ng/ml, R&D Systems). The chokeberry ex-
tract was added 24 h after starting the culture, and 3 days later the
presence of T cell subsets was analyzed by flow cytometry.
2.11. Rat insulinoma m5F (RINm5F) cell culture
RINm5F cells were a kind gift from Dr Melita Vidakovic, Institute
for Biological Research “Sinisa Stankovic”, and were purchased from
ATCC® (ATCC® CRL-11605™). The cells (4.5× 104/well) were seeded
in 96-well plates (Sardstedt) in RPMI 10% FCS, 2mM L-glutamine,
50 µM β-mercaptoethanol and antibiotics. They were cultured in the
presence or absence of a pro-inflammatory cytokine mixture – IL-1β,
TNF and IFN-γ (all from R&D Systems), 10 ng/ml each, and treated with
increasing concentrations of the chokeberry extract (100–400 µg/ml).
After 24 h of incubation, a cell viability assay was performed.
2.12. Griess test
Culture supernatants from peritoneal macrophages and splenocytes
were used for measuring nitrite accumulation as an indicator of NO
production. Equal volumes of supernatants and Griess reagent were
mixed and after 10min the mixture color intensity was detected by LKB
microplate reader (LKB Instruments, Vienna, Austria) at 540/670 nm
(for impurity corrections).
2.13. Viability assays
The viability of DC, macrophages and RIN5mF in cell cultures was
tested by MTT and crystal violet assays. After the collection of super-
natants, cells were treated with 0.5mg/ml 3-(4,5-dimethyl-2-thiazolyl)-
2,5-diphenyl-2H-tetrazolium bromide (MTT) solution (Sigma-Aldrich)
for 30min at 37 °C in a humidified incubator. After the addition of
dimethyl sulfoxide, the developed color intensity was measured by a
microplate reader at 540/670 nm. Plates were then washed and crystal
violet solution was added. After 30min at RT, the solution was thor-
oughly washed with running water and 50 μL of 33% acetic acid per
well was added. Again, the absorbance was measured by a microplate
reader at 540/670 nm.
2.14. Flow cytometry
Viable cells were used for detection of surface molecules. Surface
staining was performed in PBS 1% BSA by adding the following anti-
bodies: anti-mouse CD4 PerCP-Cyanine5.5 (rat IgG2a,κ), CD4-FITC (rat
IgG2b,κ), CD8-PE (rat IgG2a,κ), B220-FITC (rat IgG2a,κ), CD11c-PE-
Cy5 (Armenian hamster IgG), F4/80-FITC (rat IgG2a,κ), CD25-PE (rat
IgG1,λ), CD206-PE (rat IgG2b,κ), MHC II-FITC (rat IgG2b,κ), CD80-PE-
Cy5 (Armenian hamster IgG), CD86-PE-Cy5 (rat IgG2a,κ), CD19-PE-Cy5
(rat IgG2a,κ) and CD40-PE (Armenian hamster IgM,κ) (all from
ThermoFisher Scientific). The staining was performed for 45min at
4 °C. Intranuclear FoxP3 was detected by Mouse Regulatory T cell
Staining Kit according to the manufacturer’s instructions (eBioscience).
Similar procedure was used for Ki67 detection. For intracellular cyto-
kine staining, cells were stimulated with Cell Stimulation Cocktail (plus
protein transport inhibitors) (1:500, eBioscience) for 4 h. Cells were
then fixed in 2% paraformaldehyde, permeabilized and stained with the
following antibodies: anti-mouse IFN-γ-PE (rat IgG1,κ) (eBioscience) or
IL-17-PE (rat IgG1,κ) (BD Biosciences). Isotype-matched controls were
included in all experiments (eBioscience). Cells were acquired on Partec
CyFlow Space and analyzed by FlowMax software (Partec, Görlitz,
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Fig. 1. The effect of the chokeberry extract on the immune response in healthy C57BL/6 mice. (A) The proportion of F4/80+ macrophages, CD4+ T helper
lymphocytes, CD8+ cytotoxic lymphocytes, CD4+CD8+ memory cells and CD19+ B lymphocytes in the compartment of gut intraepithelial lymphocytes (IEL). (B)
The proportion of F4/80+ macrophages, CD11c+ dendritic cells, CD4+ T helper lymphocytes, CD8+ cytotoxic lymphocytes and CD19+ B lymphocytes in Peyer’s
patches. (C) The proportion of activated T helper (CD4+CD25med) or T regulatory (Treg – CD4+CD25high) cells. Representative dot plots are shown on the right hand
side. (D) Production of cytokines from splenocytes ex vivo after 24 h of cultivation. (E and F) Representative histological sections of the small intestine. p < 0.05
represents the significant change between populations or cytokine production of cells from chokeberry-treated mice compared to control mice.
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Germany). The cells were first gated on live cells (empirically de-
termined) and then further gated appropriately to the required analysis.
2.15. Phagocytosis assay
For the detection of phagocytosis, macrophages were plated in 24-
well plates at 1× 105/well and incubated at 37 °C for 1 h. After
washing with PBS, cells were incubated at 37 °C for in the presence or
absence of the chokeberry extract (25 µg/ml). After 24 h, PE-labeled
latex beads (amine-modified polystyrene particles around 1 μm in dia-
meter in the aqueous suspension, Sigma-Aldrich) were pre-opsonized in
PBS 50% FCS. Macrophages were incubated with the pre-opsonized
beads (10 beads per cell) for 1 h, after which the cells were analyzed
with cytofluorimetry (Partec CyFlow Space).
2.16. ELISAa
Cell supernatants were used for the determination of cytokine
concentration by sandwich ELISA using MaxiSorp plates (Nunck,
Rochild, Denmark) and anti-mouse paired antibodies according to the
manufacturer’s instructions. Samples were analyzed in duplicate for
murine TNF, IL-1β, IL-17, IFN-γ and IL-12 (eBioscience), TGF-β (R&D
Systems), IL-6 (Abcam, Cambridge, MA, USA) and the absorbance was
measured by a microplate reader at 450/570 nm. A standard curve was
created using known concentrations of appropriate recombinant cyto-
kines and was used to calculate the sample cytokine concentrations.
2.17. Histological examination of intestinal sections
Samples of the small intestine were fixed in 10% neutral buffered
formalin, processed to paraplast and cut on a microtome at 5 μm thick
sections. Tissue sections were stained with hematoxylin-eosin
(Biooptica, Milan, Italy). Morphometric measurements were performed
on photomicrographs acquired with digital camera Leica DFC295
(Leica, Heerbrugg, Switzerland) connected to a light microscope Leica
DM4000 B LED (Leica, Wetzlar, Germany). All elements of the small
intestine were measured (in μm) using open-source software Fiji
(Schindelin et al., 2012). Measurements were performed at the mag-
nification ×200, on 3 tissue sections for each sample. For each para-
meter 3 measurements per section were done.
2.18. Statistical analysis
Data are presented as mean ± SD. The significance of differences
between groups was determined by a two-tailed Student’s t-test.
Differences are regarded as statistically significant if p < 0.05.
Statistical analyses were performed using GraphPad Prism 5 software
(GraphPad Software, Inc., La Jolla, CA, USA).
3. Results
3.1. The effect of chokeberry extract oral consumption on the immune cells
in the gut-associated lymphoid tissue (GALT) and spleen of healthy C57BL/
6 mice
To determine whether the orally-delivered chokeberry extract af-
fected immune cells in GALT, IEL and PP cells were analyzed. The
chokeberry extract was administered for 7 days and ex vivo analysis was
performed at day 10 post-treatment. The results indicate that immune
cells in the GALT of healthy C57BL/6 mice were markedly affected by
oral consumption of the chokeberry extract. The absolute number of IEL
was mildly decreased in chokeberry-treated mice (control vs. choke-
berry-treated (11.7 ± 8.7)× 106 vs (5.9 ± 4.7)× 106, respectively,
p= 0.299), but the number of cells per PP was significantly higher after
the administration of chokeberry extract (control vs chokeberry-treated
(0.9 ± 0.4)× 106 vs (1.5 ± 0.3)× 106, respectively, p= 0.028). The
proportion of F4/80+ macrophages was significantly up-regulated,
while CD4+CD8+ and CD8+ lymphocytes were down-regulated in IEL
of chokeberry-treated mice (Fig. 1A). Proportions of CD4+ T lympho-
cytes and CD19+ B lymphocytes were comparable between groups
(Fig. 1A). Similar results were obtained when the absolute number of
cells was calculated (Table 1). Cell proportions in PP had a slightly
different distribution pattern compared to IEL. Namely, PP from cho-
keberry-treated mice had a lower proportion of F4/80+ macrophages,
CD11c+ dendritic cells, CD4+ T helper lymphocytes and CD8+ cyto-
toxic lymphocytes (Fig. 1B). Again, when comparing absolute numbers,
the only significant change was detected in the pool of B cells (CD19+)
in favor of higher numbers of B cells after chokeberry extract treatment
(Table 1). Among T helper cells, a lower proportion of activated in-
flammatory CD4+CD25med T cells was observed, while the proportion
of suppressive T regulatory (Treg) cells was similar between the control
and treated group of mice (Fig. 1C).
In order to clarify whether the observed alterations in immune cell
composition in the GALT of mice treated with the chokeberry extract
reflect its anti- or pro-inflammatory effects in vivo, we examined the
production of IFN-γ and IL-17 in ex vivo cultures of splenocytes. Oral
consumption of the chokeberry extract significantly stimulated the
production of IFN-γ, while IL-17 secretion remained unaltered
(Fig. 1D). These results imply that in addition to affecting the GALT,
chokeberry affected the systemic immune response and provoked IFN-γ
production in splenocytes.
We next evaluated the morphological characteristics of the luminal
side of the intestinum and no differences were found in the height of the
three principal layers of intestinal wall (mucosa, submucosa, muscu-
laris), the elements of mucosa (the height of intestinal villi, the depth of
Lieberkühn crypts, the height of surface epithelium, the width of
muscularis mucosa) and the width of the circular and longitudinal layer
within muscularis (Fig. 1E, F and Table 2).
Table 1
The absolute number of immune cell subsets in the intraepithelial lymphocytes (IEL) and Peyers’s patches (PP) of healthy C57BL/6 mice treated with chokeberry
extract.
(×106 cells) Control (IEL) Chokeberry (IEL) Control (PP) Chokeberry (PP)
F4/80+ 0.092 ± 0.044 0.268 ± 0.105* 0.005 ± 0.002 0.006 ± 0.001
CD11c+ NM NM 0.057 ± 0.031 0.072 ± 0.012
CD4+ 2.0 ± 1.6 1.2 ± 0.4 0.123 ± 0.049 0.157 ± 0.036
CD8+ 7.9 ± 4.7 2.2 ± 1.6* 0.073 ± 0.033 0.076 ± 0.012
CD19+ 0.18 ± 0.10 0.12 ± 0.12 0.484 ± 0.192 0.868 ± 0.110*
NM – not measured.
* p < 0.05, statistical significance between the absolute numbers of IEL and PP of chokeberry extract-treated vs untreated (control) C57BL/6 mice.
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3.2. The effects of oral consumption of the chokeberry extract on T1D in
mice
Since our results indicated that the chokeberry extract had a pro-
found impact on immune cells in vivo, we next investigated its effects in
the model of T1D induced by multiple low doses of STZ in C57BL/6
mice. The chokeberry extract was orally consumed starting from the
first injection of STZ, once a day for 7 days in total (Fig. 2A). A higher
concentration of chokeberry extract (200mg/kg bw) was shown to be
lethal in 2 out of 7 mice on day 7 after T1D induction. This group of
mice exhibited significant weight loss by day 7 (Fig. 2B) and hy-
perglycemia on day 14 after T1D induction (Fig. 2C). We then in-
vestigated the effect of a lower dose of chokeberry extract (50mg/kg
bw). Similarly, oral administration of the extract resulted in higher
blood glucose levels compared to untreated diabetic mice (Fig. 2E and
F), while no change in the body weight was observed (Fig. 2D). In
contrast to the diabetic mice, chokeberry administration to healthy
C57BL/6 mice did not provoke the increase of blood glucose levels
compared to untreated mice at day 7 post-treatment (8.5 ± 1.7 vs
7.3 ± 1mmol/L, respectively). The observed elevation of glycemia in
diabetic animals was probably not a result of a direct harmful effect of
the chokeberry extract on pancreatic β-cells, since its application in
vitro on RIN5mF cells (insulinoma cell line) caused significant protec-
tion from the detrimental influence of pro-inflammatory cytokines
(Fig. 2G). Since the chokeberry extract increased glycemia, the next
step was to investigate the effect of chokeberry on the cells of the im-
mune system that are involved in the inflammatory/autoimmune re-
sponse during T1D.
3.3. The influence of the chokeberry extract on antigen-presenting cells in
vitro
In order to further delineate the effect of chokeberry on immune
cells, we performed in vitro studies. First, we examined the effect of the
chokeberry extract on innate immune cells. DC were exposed to the
maturation signal (LPS) in the presence or absence of various con-
centrations of the chokeberry extract. The viability of DC did not de-
crease after 48 h of incubation with the extract (Fig. 3A and B), while
the presence of the chokeberry extract boosted LPS-driven production
of NO (Fig. 3C). Since chokeberry slightly increased the number of DC
(measured by crystal violet), when NO production was normalized to
the number of cells, the observed increase in NO was annulled. The
production of pro-inflammatory cytokines IL-β and IL-6 remained un-
altered in DC cultures exposed to the chokeberry extract, while the
production of TNF was increased (Fig. 3D).
The chokeberry extract exerted similar effects on in vitro cultured
macrophages. The viability of macrophages was not affected by the
chokeberry extract in any of the tested concentrations (Fig. 4A). The
chokeberry extract increased NO production by macrophages (Fig. 4B)
and increased the proportion of macrophages expressing the co-stimu-
latory molecule CD86 (Fig. 4C), while it increased the proportion of
both pro-inflammatory M1 macrophages and anti-inflammatory M2
macrophages (Fig. 4D). The ability of macrophages to phagocytize
particles in vitro was significantly increased after the chokeberry
treatment (Fig. 4E). The production of pro-inflammatory IL-6 and IL-12
was increased in macrophage cultures after chokeberry extract treat-
ment, while IL-1β and TNF production remained unchanged (Fig. 4F).
These results demonstrate the stimulatory effect of chokeberry extract
on innate immunity cells in vitro.
3.4. The effect of the chokeberry extract on adaptive immune cells in vitro
To determine the effect of the chokeberry extract on cells of ac-
quired immunity, a suspension of splenocytes was subjected to choke-
berry extract treatment in the presence of ConA. After 48 h of incuba-
tion, an MTT test revealed that chokeberry extract increased theTa
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number of viable cells (ConA-treated vs. chokeberry extract+ ConA-
treated 0.0800 ± 0.0017 vs 0.0917 ± 0.0051, respectively,
p= 0.001) as well as the proportion of CD4+, CD8+ and B220+ B
lymphocytes (Fig. 5A). The production of IL-17, IFN-γ and TGF-β did
not change after chokeberry extract treatment (Fig. 5B).
We further examined whether the chokeberry extract impacts in
vitro induced differentiation of T helper cells. To this end, we cultured
naïve CD4+CD25- cells in conditions that favor differentiation of Th1,
Th17 or Treg cells in the presence of the chokeberry extract. The extract
promoted Th1 cell differentiation and suppressed Treg cell differ-
entiation, while no effect on Th17 cells was observed after 5 days of
cultivation (Fig. 5C). The expression of signature cytokines IFN-γ (Th1)
and IL-17 (Th17) was not altered in the presence of chokeberry extract
(Fig. 5D). These results suggest that the chokeberry extract favored the
differentiation of pro-inflammatory Th1 cells.
3.5. HPLC analysis of the chokeberry extract
In order to compare the composition of our chokeberry extract to
others, phenolic constituents were quantified using the HPLC method.
Cyanidin-3-galactoside was the main anthocyanin compound (0.34mg/
g), followed by cyanidin-3-arabinoside (0.16 mg/g) and cyanidin-3-
glucoside (0.06 mg/g). Quercetin derivatives were the major flavonoids
in the chokeberry, with quercetin-3-glucoside, quercetin-3-galactoside
Fig. 2. The effect of the chokeberry extract on T1D
pathogenesis. (A) Schematic overview of the T1D
induction and chokeberry treatment of C57BL/6
mice. (B) Body weight and survival and (C) glycemia
of mice treated with chokeberry extract (200mg/kg
bw). (D) Body weight, (E) diabetes incidence and (F)
glycemia of mice treated with chokeberry extract
(50mg/kg bw). (G) The viability of RINm5F treated
with cytokines (IL-1β+TNF+ IFN-γ) in the pre-
sence of the chokeberry extract. Results were ob-
tained from 7 mice per group. p < 0.05 represents
the significant change between chokeberry-treated
mice compared to control mice or choke-
berry+ cytokine-treated RIN5mF cells vs cytokine-
treated cells.
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and quercetin-3-rutinoside found in amounts of 0.15mg/g, 0.31mg/g,
and 0.28mg/g, respectively. Chlorogenic acid was the main phenolic
acid, and its content was 3.53mg/g. The amount of total proantho-
cyanidins was 36.5mg CE/g. This phenolic pattern is in agreement with
previously reported data (Kulling & Rawel, 2008).
4. Discussion
This study points to the pro-inflammatory properties of the choke-
berry extract: it exacerbated T1D clinical signs in C57BL/6 mice, trig-
gered a significant perturbation of immune cell composition within the
GALT and stimulated pro-inflammatory features of innate and adaptive
immune cells in vitro.
Chokeberry extracts have already been used in animal models of
various inflammatory conditions. The applied doses have ranged from
10 to 2680mg/kg bw (Kang et al., 2017; Valcheva-Kuzmanova,
Kuzmanov, Kuzmanova, & Tzaneva, 2018) and each of them was well
tolerated and exerted biological effects. We have first chosen the dose of
200mg/kg bw according to the study by Lee et al. (2016) that was
performed on ICR mice. However, the dose of 200mg/kg bw of our
chokeberry extract showed lethal effects in the diabetes model in
C57BL/6 mice. The lower dose of the chokeberry extract (selected ac-
cording to our study performed on spontaneously hypertensive rats)
(Ćujić et al., 2018) had no lethal effects, but it did increase blood
glucose levels in diabetic C57BL/6 mice. This finding is in contrast to
the study which demonstrated beneficial effects of a chokeberry extract
on hyperglycemia in ICD mice (Jeon et al., 2018). In a human inter-
vention study, a daily intake of 200mL of chokeberry juice over a
period of 3months was effective in lowering fasting glucose levels in
patients with non-insulin dependent diabetes (Simeonov et al., 2002).
Although chokeberry fruit contains high amounts of sugar, with sorbitol
being the most abundant, the results of Simeonov et al. suggest that this
sugar content does not raise blood glycemia levels. Therefore, the in-
creased glycemia in mice with T1D could be attributed to the choke-
berry-mediated influence on immune cells rather than the direct con-
tribution of the sugar content to the overall blood glucose level.
Additionally, the aggravation of T1D by the chokeberry extract was
most probably not prompted by its interference with pancreatic β-cells.
This is corroborated by the finding that in vitro application of the
chokeberry extract on RIN5mF β-cell line protected the cells from the
cytotoxic influence of pro-inflammatory cytokines. Therefore, our next
aim was to investigate the effect of chokeberry extract on immune cells
in vivo and in vitro.
Generally, chokeberry extracts contain mixtures of biologically-ac-
tive substances that inhibit inflammation. Polyphenol compounds,
more precisely anthocyanins, are responsible for the anti-inflammatory
properties of berries (Joseph, Edirisinghe, & Burton-Freeman, 2014;
Martin et al., 2014). According to literature, the main anthocyanin
compounds in chokeberry extracts - cyanidin and its glucosides show an
extremely potent anti-inflammatory activity (Jung, Kwak, & Hwang,
2014; Wang et al., 1999). In addition to specific constituents that show
anti-inflammatory effects, the application of a whole berry extract was
highly operative in preventing inflammation as well. For example, oral
administration of a chokeberry extract inhibited prostaglandin E2
production in DSS-induced colitis (Kang et al., 2017), down-regulated
inflammatory markers in LPS-induced uveitis (Ohgami et al., 2005),
Fig. 3. The effect of the chokeberry extract on DC in vitro. Viability measured by (A) crystal violet or (B) MTT assay and (C) NO production of DC stimulated with LPS
in the presence or absence of increasing concentrations of the chokeberry extract. (D) Production of cytokines from DC after 24 h of cultivation. p < 0.05 represents
the significant change between populations or cytokine production of chokeberry-treated cells compared to adequate controls.
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and decreased the levels of NO, IL-6, and TNF-α in ex vivo LPS-stimu-
lated macrophages (Kang et al., 2017). Our results suggested the op-
posite effects: the chokeberry extract stimulates the pro-inflammatory
functions of both innate and adaptive cells of the immune response in
vitro. As we have excluded the possible contamination of the extract
with either live bacteria or endotoxin (LPS) that could potentially ac-
tivate immune cells, the discrepancy in the effect between this specific
chokeberry extract and other ones can be only attributed to different
extraction procedures and subsequent difference in extract composi-
tion. Although the phenolic content is similar to some of the chokeberry
Fig. 4. The effect of the chokeberry extract on
macrophages in vitro. (A) Viability and (B) NO
production of peritoneal macrophages stimulated
with IFN-γ+LPS in the presence or absence of
increasing concentrations of the chokeberry ex-
tract. (C) The proportion of MHC II+ macro-
phages expressing CD80 or CD86 co-stimulatory
molecules after the treatment with the chokeberry
extract. (D) The proportion of M1 (F4/
80+CD40+) and M2 (F4/80+CD206+) macro-
phages after the treatment with the chokeberry
extract (25 μg/ml). Representative dot plots of
25 μg/ml chokeberry treatments are shown on the
right hand side. (E) The proportion of macro-
phages that phagocytized PE-labeled latex beads,
analyzed by flow cytometry after 24 h of cultiva-
tion. (F) Production of cytokines from macro-
phages after 24 h of cultivation. p < 0.05 re-
presents the significant change between
populations or cytokine production of choke-
berry-treated cells compared to adequate con-
trols.
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extracts described by Kulling and Rawel (2008), the other constituents
such as organic acids, sugars, dietary fiber, minerals, vitamins and
proteins could be different. Therefore, the ratio between specific
bioactive compounds can result in different bioactivity. Also, the con-
tent of the extract is highly influenced by localization, culture condi-
tions, depends on the variety of species, season and harvest date (Sidor
& Gramza-Michałowska, 2019). Moreover, in our study the chokeberry
extract dose of 200mg/kg bw exerted lethal effects, which is in contrast
to reported studies. This finding further implies a different composition
of our chokeberry extract.
DC and macrophages were the main representatives of innate im-
munity affected by the chokeberry extract. NO secretion from macro-
phages was increased after chokeberry extract administration. NO is a
pro-inflammatory molecule that participates in the elimination of in-
vading microbes and could act in an anti-proliferative manner re-
garding T cells (Fonseca et al., 2003). The production of NO in DC
seemed to be higher after the chokeberry treatment, but when nor-
malized to the number of viable DC, there was no statistical sig-
nificance. The administration of LPS decreased the viability of DC,
while the chokeberry extract mildly prevented LPS-induced cell death.
Overall, it can be concluded that the chokeberry extract exerted a
biological effect on DC in vitro, either through the preservation of their
viability or NO induction. Along with NO, other mediators such as TNF
and IL-6 produced by phagocytes were stimulated by the chokeberry
extract. To support the increased activation of macrophages, their
phagocytic ability was also enhanced in the presence of the chokeberry
extract. Although all data point to the stimulation of M1 pro-in-
flammatory macrophages by the extract, the number of M2 anti-in-
flammatory macrophages was elevated as well, suggesting an overall
stimulatory effect of chokeberry on macrophage proliferation. The ef-
fect of the chokeberry extract on the representatives of adaptive im-
munity, Th1, Th17 or Treg cells, was again in favor of inflammation.
Namely, chokeberry specifically stimulated Th1 and inhibited Treg
cells. Th1 cell differentiation is a process dependent on IL-12 (Zhang,
Zhang, Gu, & Sun, 2014). The chokeberry extract stimulated the pro-
duction of this cytokine from phagocytes, and this might be one of the
reasons behind stimulated Th1 differentiation. In concordance with the
generally pro-inflammatory effects, Treg cell differentiation was par-
tially blocked after the treatment with the chokeberry extract. Treg cells
are important for the maintenance of immune system homeostasis, as
they inhibit effector T cell proliferation. Therefore, the observed ne-
gative effect on Treg cells may have been another reason for the sti-
mulated Th1 differentiation. Interestingly, although the chokeberry
extract stimulated IL-6 production in macrophages, the differentiation
of Th17 cells remained unaltered. Th17 cells require the presence of
both IL-6 and TGF-β. Therefore, the reason for this effect might be
found in the unchanged TGF-β production.
When given orally, the chokeberry treatment enhanced the number
of cells within the PP in healthy mice, either by stimulating their in situ
proliferation or by attracting them from other lymphoid tissues.
Furthermore, the number of macrophages was increased in the GALT,
as well as ex vivo splenic production of IFN-γ. However, we found a
reduction in effector CD4+CD25med cell proportion in the GALT as well
as the proportion of highly activated CD4+CD8+ memory cells (Pahar,
Lackner, & Veazey, 2006). These results suggest that oral consumption
of chokeberry extract in healthy mice affects the proportions of immune
cells in GALT.
To date there are very little data on pro-inflammatory effects of
plant extracts in general (Yahfoufi, Alsadi, Jambi, & Matar, 2018). Si-
milarly to the chokeberry extract, the water extract of litchi (Asian
cherry) stimulates pro-inflammatory mediators IL-1β, inducible NO
synthase and cyclooxygenase-2 in a macrophage cell line (Wang, Hu,
Yan, Ma, & Deng, 2016). Specific proteins were identified in litchi as
the bioactive compounds that caused the observed effects. Therefore,
Fig. 5. The effect of the chokeberry extract on lymphocytes in vitro. Splenocytes were treated in vitro with the chokeberry extract (25 μg/ml) and cell populations
were analyzed 24 h after the addition of chokeberry (A) and cytokine production was measured in the presence of ConA (B). (C) Purified CD4+CD25- lymphocytes
were stimulated either toward Th1 cell differentiation (anti-CD3+ anti-CD28 antibodies+ IL-2+ IL-12) or Th17 (anti-CD3+ anti-CD28 antibodies+TGF-β+IL-
6) or Treg (anti-CD3+ anti-CD28 antibodies+ IL-2+TGF-β) for 5 days. The chokeberry extract was added 24 h after the initiation of differentiation. Representative
dot plots are shown on the right hand side. (D) Cytokine expression within Th1 and Th17 lymphocytes measured as mean fluorescence intensity (MFI). p < 0.05
represents the significant change between populations of chokeberry-treated cells compared to adequate controls.
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the observed chokeberry extract effect can be attributed to proteins.
Furthermore, citrus-derived pectins may cause an increased production
of IL-17, IFN-γ and TNF from mouse splenocytes in vivo (Merheb, Abdel-
Massih, & Karam, 2019). Pectins are also highly abundant in choke-
berry extracts, with pectin content similar to those of apples or pears,
fruits that have high pectin content (Nawirska & Kwaśniewska, 2005).
Therefore, the pro-inflammatory nature of the chokeberry extract may
be related to its pectin levels. Of note, herbal extracts that show anti-
cancer properties may mediate their effects through the stimulation of
the immune response. For example, extracts from Astragalus species
stimulate T cell activation and the production of pro-inflammatory
cytokines in vivo and in vitro. These effects are attributed to astragalo-
sides (Qi, Gao, Hou, & Wan, 2017). It is still uncertain which con-
stituents of our chokeberry extract causes the observed pro-in-
flammatory effects, but it can be speculated that the specific ratio
between organic compounds, vitamins and minerals present in the
chokeberry extract (Kulling & Rawel, 2008; Nawirska & Kwaśniewska,
2005) could provoke such an effect, which warrants further investiga-
tion. One of the possible reasons for the observed pro-inflammatory
effects of our chokeberry extract could be the low content of poly-
phenols. For example, in contrast to an extract used in the treatment of
uveitis where the extract contained 16.9% of polyphenols (Ohgami
et al., 2005), our chokeberry extract contains only 4%.
The observed feature of the chokeberry extract used in our study
could be utilized in the fight against infections or cancer, in which an
enhanced pro-inflammatory response is beneficial. The results of this
study point to the necessity of thorough investigation of plant extracts
before their commercialization.
5. Ethics statements
Ethic Committee of the Institute for Biological Research “Sinisa
Stankovic” approved all experimental procedures with C57BL/6 mice
(App. No 02-11/18 - 01-2420) and they comply with the ARRIVE
guidelines and were in accordance with the Directive 2010/63/EU.
CRediT authorship contribution statement
Dragica Gajic: Data curation, Investigation, Methodology, Formal
analysis, Writing - review & editing. Tamara Saksida: Data curation,
Investigation, Methodology, Formal analysis, Writing - review &
editing. Ivan Koprivica: Investigation, Methodology, Writing - review
& editing.Milica Vujicic: Investigation, Methodology, Writing - review
& editing. Sanja Despotovic: Visualization, Writing - review & editing.
Katarina Savikin: Investigation, Methodology, Writing - review &
editing. Teodora Jankovic: Investigation, Methodology, Writing - re-
view & editing. Ivana Stojanovic: Conceptualization, Data curation,
Formal analysis, Supervision, Investigation, Writing - original draft,
Writing - review & editing.
Declaration of Competing Interest
None.
Acknowledgments
We would like to thank Dr. Nada Pejnovic (Institute for Biological
Research “Sinisa Stankovic”- National Institute of Republic of Serbia,
University of Belgrade) for the proofreading the manuscript and Dr.
Lidija Senerovic (Institute of Molecular Genetics and Genetic
Engineering, University of Belgrade) for testing the sterility of the
chokeberry extract.
Funding
This work was supported by the Ministry of Education, Science and
Technological Development, Republic of Serbia [grant numbers
173013, III46013].
Appendix A. Supplementary material
Supplementary data associated with this article can be found, in the
online version, at https://doi.org/10.1016/j.jff.2020.103836.
References
Appel, K., Meiser, P., Millán, E., Collado, J. A., Rose, T., Gras, C. C., ... Muñoz, E. (2015).
Chokeberry (Aronia melanocarpa (Michx.) Elliot) concentrate inhibits NF-κB and sy-
nergizes with selenium to inhibit the release of pro-inflammatory mediators in
macrophages. Fitoterapia, 105, 73–82. https://doi.org/10.1016/j.fitote.2015.06.009.
Banjari, I., Misir, A., Šavikin, K., Jokić, S., Molnar, M., De Zoysa, H. K. S., & Waisundara,
V. Y. (2017). Antidiabetic effects of Aronia melanocarpa and its other therapeutic
properties. Frontiers in Nutrition, 4, 53–59. https://doi.org/10.3389/fnut.2017.
00053.
Borowska, S., & Brzóska, M. M. (2016). Chokeberries (Aronia melanocarpa) and their
products as a possible means for the prevention and treatment of non communicable
diseases and unfavorable health effects due to exposure to xenobiotics. Comprehensive
Reviews in Food Science and Food Safety, 15, 982–1017. https://doi.org/10.1111/
1541-4337.12221.
Cetkovic-Cvrlje, M., Thinamany, S., & Bruner, K. A. (2017). Bisphenol A (BPA) aggravates
multiple low-dose streptozotocin-induced Type 1 diabetes in C57BL/6 mice. Journal
of Immunotoxicology. 14, 160–168. https://doi.org/10.1080/1547691X.2017.
1334722.
Couter, C. J., & Surana, N. K. (2016). Isolation and flow cytometric characterization of
murine small intestinal lymphocytes. Journal of Visualized Experiments. 8, 111.
https://doi.org/10.3791/54114.
Ćujić, N., Šavikin, K., Janković, T., Pljevljakušić, D., Zdunić, G., & Ibrić, S. (2016).
Optimization of polyphenols extraction from dried chokeberry using maceration as
traditional technique. Food Chemistry, 194, 135–142. https://doi.org/10.1016/j.
foodchem.2015.08.008.
Ćujić, N., Šavikin, K., Miloradović, Z., Ivanov, M., Vajić, U. J., Karanović, D., ...
Mihailović-Stanojević, N. (2018). Characterization of dried chokeberry fruit extract
and its chronic effects on blood pressure and oxidative stress in spontaneously hy-
pertensive rats. Journal of Functional Foods, 44, 330–339.
Djedovic, N., Mansilla, M. J., Jevtić, B., Navarro-Barriuso, J., Saksida, T., Martínez-
Cáceres, E. M., & Miljković, Ð. (2019). Ethyl pyruvate induces tolerogenic dendritic
cells. Frontiers in Immunology, 10, 157. https://doi.org/10.3389/fimmu.2019.00157.
Fonseca, S. G., Romão, P. R., Figueiredo, F., Morais, R. H., Lima, H. C., Ferreira, S. H., &
Cunha, F. Q. (2003). TNF-alpha mediates the induction of nitric oxide synthase in
macrophages but not in neutrophils in experimental cutaneous leishmaniasis.
European Journal of Immunology, 33, 2297–2306.
Francik, R., Kro'sniak, M., Sanocka, I., Barto'n, H., Hebda, T., & Francik, S. (2014). Aronia
melanocarpa treatment and antioxidant status in selected tissues in Wistar rats.
BioMed Research International, 2014, 1–9. https://doi.org/10.1155/2014/457085.
Handeland, M., Grude, N., Torp, T., & Slimestad, R. (2014). Black chokeberry juice
(Aronia melanocarpa) reduces incidences of urinary tract infection among nursing
home residents in the long term–a pilot study. Nutrition Research, 34, 518–525.
https://doi.org/10.1016/j.nutres.2014.05.005.
Jeon, Y. D., Kang, S. H., Moon, K. H., Lee, J. H., Kim, D. G., Kim, W., ... Jin, J. (2018). S.
The effect of aronia berry on type 1 diabetes In Vivo and In Vitro. Journal of Medicinal
Food, 21, 244–253. https://doi.org/10.1089/jmf.2017.3939.
Joseph, S. V., Edirisinghe, I., & Burton-Freeman, B. M. (2014). Berries: Anti-inflammatory
effects in humans. Journal of Agricultural and Food Chemistry, 62, 3886–3903. https://
doi.org/10.1021/jf4044056.
Jung, H., Kwak, H. K., & Hwang, K. T. (2014). Antioxidant and antiinflammatory activ-
ities of cyanidin-3-glucoside and cyanidin-3-rutinoside in hydrogen peroxide and li-
popolysaccharide-treated RAW264.7. Food Science and Biotechnology, 23, 2053–2062.
https://doi.org/10.1007/s10068-014-0279-x.
Kähkönen, M. P., Hopia, A. I., & Heinonen, M. (2001). Berry phenolics and their anti-
oxidant activity. Journal of Agricultural Food Chemistry, 49, 4076–4082. https://doi.
org/10.1021/jf010152t.
Kang, S. H., Jeon, Y. D., Moon, K. H., Lee, J. H., Kim, D. G., Kim, W., ... Jin, J. S. (2017).
Aronia berry extract ameliorates the severity of dextran sodium sulfate-induced ul-
cerative colitis in mice. Journal of Medicinal Food, 20, 667–675. https://doi.org/10.
1089/jmf.2016.3822.
Koprivica, I., Gajic, D., Saksida, T., Cavalli, E., Auci, D., Despotovic, S., ... Stojanovic, I.
(2019). Orally delivered all-trans-retinoic acid- and transforming growth factor-β-
loaded microparticles ameliorate type 1 diabetes in mice. European Journal of
Pharmacology, 864, 172721. https://doi.org/10.1016/j.ejphar.2019.172721.
Kulling, S. E., & Rawel, H. M. (2008). Chokeberry (Aronia melanocarpa) - A review on the
characteristic components and potential health effects. Planta Medica, 74,
1625–1634. https://doi.org/10.1055/s-0028-1088306.
Lee, H. Y., Weon, J. B., Jung, Y. S., Kim, N. Y., Kim, M. K., & Ma, C. J. (2016). Cognitive-
enhancing effect of Aronia melanocarpa extract against memory impairment induced
by scopolamine in mice. Evidence-Based Complementary and Alternative Medicine,
2016, 6145926. https://doi.org/10.1155/2016/6145926.
Lee, K. P., Choi, N. H., Kim, H. S., Ahn, S., Park, I. S., & Lee, D. W. (2018). Anti-neu-
roinflammatory effects of ethanolic extract of black chokeberry (Aronia melanocapa
L.) in lipopolysaccharide-stimulated BV2 cells and ICR mice. Nutrition Research and
D. Gajic, et al. Journal of Functional Foods 66 (2020) 103836
11
Practice, 12, 13–19. https://doi.org/10.4162/nrp.2018.12.1.13.
Li, Y. G., Tanner, G., & Larkin, P. (1996). The DMACA-HCl protocol and the threshold
proanthocyanidin content for bloat safety in forage legumes. Journal of the Science of
Food and Agriculture, 70, 89–101.
Martin, D. A., Taheri, R., Brand, M. H., Draghi, A., Sylvester, F. A., & Bolling, B. W.
(2014). Anti-inflammatory activity of aronia berry extracts in murine splenocytes.
Journal of Functional Foods, 8, 68–75. https://doi.org/10.1016/j.jff.2014.03.004.
Merheb, R., Abdel-Massih, R. M., & Karam, M. C. (2019). Immunomodulatory effect of
natural and modified Citrus pectin on cytokine levels in the spleen of BALB/c mice.
International Journal of Biological Macromolecules, 121, 1–5. https://doi.org/10.1016/
j.ijbiomac.2018.09.189.
Nawirska, A., & Kwaśniewska, M. (2005). Dietary fibre fractions from fruit processing
waste. Food Chemistry, 91, 221–225. https://doi.org/10.1016/j.foodchem.2003.10.
005.
Ohgami, K., Ilieva, I., Shiratori, K., Koyama, Y., Jin, X. H., Yoshida, K., ... Ohno, S. (2005).
Anti-inflammatory effects of aronia extract on rat endotoxin-induced uveitis.
Investigative Ophthalmology & Visual Science, 46, 275–281. https://doi.org/10.1167/
iovs.04-0715.
Pahar, B., Lackner, A. A., & Veazey, R. S. (2006). Intestinal double-positive CD4+CD8+ T
cells are highly activated memory cells with an increased capacity to produce cyto-
kines. European Journal of Immunology, 36, 583–592.
Pei, R., Martin, D. A., Valdez, J. C., Liu, J., Kerby, R. L., Rey, F. E., ... Bolling, B. W.
(2019). Dietary prevention of colitis by aronia berry is mediated through increased
Th17 and treg. Molecular Nutrition & Food Research, 63, e1800985. https://doi.org/
10.1002/mnfr.201800985.
Qi, Y., Gao, F., Hou, L., & Wan, C. (2017). Anti-inflammatory and immunostimulatory
activities of astragalosides. The American Journal of Chinese Medicine, 45, 1157–1167.
https://doi.org/10.1142/S0192415X1750063X.
Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., ...
Cardona, A. (2012). Fiji: An open-source platform for biological-image analysis.
Nature methods, 9, 676–682. https://doi.org/10.1038/nmeth.2019.
Sidor, A., & Gramza-Michałowska, A. (2019). Black chokeberry aronia melanocarpa L.-A
qualitative composition, phenolic profile and antioxidant potential. Molecules, 24,
E3710. https://doi.org/10.3390/molecules24203710.
Simeonov, S. B., Botushanov, N. P., Karahanian, E. B., Pavlova, M. B., Husianitis, H. K., &
Troev, D. M. (2002). Effects of Aronia melanocarpa juice as part of the dietary regimen
in patients with diabetes mellitus. Folia Medica (Plovdiv), 44, 20–23.
Skoczyñska, A., Jêdrychowska, I., Porêba, R., AffelskaJercha, A., Turczyn, B.,
Wojakowska, A., & Andrzejak, R. (2007). Influence of chokeberry juice on arterial
blood pressure and lipid parameters in men with mild hypercholesterolemia.
Pharmacological Reports, 59, 177–182.
Thi, N. D., & Hwang, E. S. (2018a). Effects of black chokeberry extracts on metatasis and
cell-cycle arrest in SK-Hep1 human liver cancer cell line. Asian Pacific Journal of
Tropical Biomedicine, 8, 285–291. https://doi.org/10.4103/2221-1691.235313.
Thi, N. D., & Hwang, E. S. (2018b). Anti-cancer and anti-inflammatory activities of aronia
(Aronia melanocarpa) leaves. Asian Pacific Journal of Tropical Biomedicine, 8, 586–592.
https://doi.org/10.4103/2221-1691.248095.
Valcheva-Kuzmanova, S., Kuzmanov, A., Kuzmanova, V., & Tzaneva, M. (2018). Aronia
melanocarpa fruit juice ameliorates the symptoms of inflammatory bowel disease in
TNBS-induced colitis in rats. Food and Chemical Toxicology, 113, 33–39. https://doi.
org/10.1016/j.fct.2018.01.011.
Valcheva-Kuzmanova, S., Kuzmanov, K., Tancheva, S., & Belcheva, A. (2007).
Hypoglycemic and hypolipidemic effects of Aronia melanocarpa fruit juice in strep-
tozotocin-induced diabetic rats. Methods and Findings in Experimental and Clinical
Pharmacology, 29, 101–105. https://doi.org/10.1358/mf.2007.29.2.1075349.
Vujicic, M., Nikolic, I., Kontogianni, V. G., Saksida, T., Charisiadis, P., Orescanin-Dusic,
Z., ... Stojanovic, I. (2015). Methanolic extract of Origanum vulgare ameliorates type 1
diabetes through antioxidant, anti-inflammatory and anti-apoptotic activity. British
Journal of Nutrition, 113, 770–782. https://doi.org/10.1017/S0007114514004048.
Wang, H., Nair, M. G., Strasburg, G. M., Chang, Y. C., Booren, A. M., Gray, J. I., & DeWitt,
D. L. (1999). Antioxidant and antiinflammatory activities of anthocyanins and their
aglycon, cyanidin, from tart cherries. Journal of Natural Products, 62, 294–1196.
https://doi.org/10.1021/np980501m.
Wang, X., Hu, X., Yan, H., Ma, Z., & Deng, X. (2016). Pro-inflammatory effects of a litchi
protein extract in murine RAW264.7 macrophages. Horticulture Research, 3, 16017.
https://doi.org/10.1038/hortres.2016.17.
Wu, X. L., Gu, L. W., Prior, R. L., & McKay, S. (2004). Characterization of anthocyanins
and proanthocyanidins in some cultivars of Ribes, Aronia, and Sambucus and their
antioxidant capacity. Journal of Agricultural and Food Chemistry, 52, 7846–7856.
https://doi.org/10.1021/jf0486850.
Yahfoufi, N., Alsadi, N., Jambi, M., & Matar, C. (2018). The Immunomodulatory and anti-
inflammatory role of polyphenols. Nutrients, 10, 11. https://doi.org/10.3390/
nu10111618 pii: E1618.
Zapolska-Downar, D., et al. (2012). Aronia melanocarpa fruit extract exhibits anti-in-
flammatory activity in human aortic endothelial cells. European Journal of Nutrition,
51, 563–572. https://doi.org/10.1007/s00394-011-0240-1.
Zhang, Y., Zhang, Y., Gu, W., & Sun, B. (2014). TH1/TH2 cell differentiation and mole-
cular signals. Advances in Experimental Medicine and Biology, 841, 15–44. https://doi.
org/10.1007/978-94-017-9487-9_2.
Zheng, W., & Wang, S. Y. (2003). Oxygen radical absorbing capacity of phenolics in
blueberries, cranberries, chokeberries, and lingonberries. Journal of Agricultural Food
Chemistry, 51, 502–509. https://doi.org/10.1021/jf020728u.
D. Gajic, et al. Journal of Functional Foods 66 (2020) 103836
12
